All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the International Symposium on Hodgkin Lymphoma (ISHL) 2022 meeting, the Lymphoma Hub spoke with Astrid Pavlovsky, Fundaleu, Buenos Aires, AR. We asked, When and how should treatment be modified for older patients with HL?
When and how should treatment be modified for older patients with HL?
Pavlovsky begins by outlining why patients with HL >60 years of age typically have poor outcomes compared with younger patients. Pavlovsky then discusses the challenges faced when treating older patients with HL and reviews the latest clinical trial data for novel agents and combination therapies in this difficult-to-treat population.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Bendamustine plus ofatumumab for naïve, elderly patients with DLBCL: Results from a phase II trial
This trial investigated the efficacy of bendamustine and ofatumumab in elderly patients with newly-diagnosed DLBCL, who were not good candidates for...
Results from a phase II study: brentuximab plus DTIC is a good choice in elderly, front-line HL patients
The results of this study ought to serve as a template and give rise to additional studies of novel induction regimens for elderly HL patients.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox